The global stem cell therapy market is expected to reach $330 million by 2020, at a CAGR of 39.5% from 2015 to 2020.
The global stem cell therapy market on the basis of the mode of treatment is segmented into allogeneic and autologous stem cell therapy. The allogeneic stem cell therapy is expected to command the largest share of the market in 2015, and the allogeneic stem cell therapy segment is expected to grow at the highest CAGR of 40% in the forecast period (2015-2020).
Based on the therapeutic applications, the global stem cell therapy market is segmented into eye diseases, metabolic diseases, GIT diseases, musculoskeletal disorders, immune system diseases, CNS diseases; CVS diseases, wounds and injuries, and others. Immune system diseases are expected to command the largest share of the global market in 2015. The Central Nervous System (CNS) disease segment will be the fastest-growing segment of the global market in the forecast period.
Speak to Analyst: http://www.marketsandmarkets.com/speaktoanalyst.asp?id=48
A number of factors such as increasing funding from government and private organizations, growing industry focus on stem cell research, and increasing global awareness about stem cell therapies through various organizations are driving the growth of the global market. Furthermore, increasing funding for new stem cell lines, development of advanced genomic methods for stem cell analysis, and rising approvals of clinical trials for stem cells therapy are other factors that are propelling the growth of the market.
In addition, increasing stem cell researches in developing markets, emergence of the induced pluripotent stem (iPS) cells as an alternative to ESCs, and the evolution of novel stem cell therapies unfolds new avenues for the growth of this market.
Based on geography, the market is divided into North America, Asia-Pacific, Europe, and the Rest of the World (RoW). In 2015, North America is expected to hold the largest share in the global market, followed by Asia-Pacific, Europe, and the RoW (Rest of the World). The Asia-Pacific region is estimated to grow at the highest CAGR in the forecast period, owing to factors such as presence of huge patient population base, increasing regulatory support through favorable government policies, strong product pipelines of stem cell therapies, and rising licensing activities.
Major players such as Mesoblast Ltd. (Australia), Aastrom Biosciences Inc. (U.S.), Celgene Corporation (U.S.), and StemCells, Inc.(U.S.) are adopting several growth strategies such as new product approvals, partnerships, agreements, collaborations, joint ventures, mergers, and acquisitions in order to keep pace with the evolving industry trends.
MarketsandMarkets is a global market research and consulting company based in the U.S. We publish strategically analyzed market research reports and serve as a business intelligence partner to Fortune 500 companies across the world.
MarketsandMarkets also provides multi-client reports, company profiles, databases, and custom research services. MarketsandMarkets covers thirteen industry verticals; including advanced materials, automotive and transportation, banking and financial services, biotechnology, chemicals, consumer goods, telecommunications and IT, energy and power, food and beverages, industrial automation, healthcare IT, medical devices, pharmaceuticals, semiconductor and electronics, aerospace & defense.
We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository.
North - Dominion Plaza
17304 Preston Road
Suite 800, Dallas, TX 75252
Visit MarketsandMarkets Blog @ http://mnmblog.org/market-research/healthcare/pharmaceuticals
Connect with us on LinkedIn @ http://www.linkedin.com/company/marketsandmarkets